Truepoint Inc. cut its stake in Pfizer (NYSE:PFE) by 46.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,801 shares of the biopharmaceutical company’s stock after selling 5,056 shares during the period. Truepoint Inc.’s holdings in Pfizer were worth $210,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Delphi Private Advisors LLC lifted its stake in Pfizer by 84.3% during the 4th quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 1,600 shares during the period. Americafirst Capital Management LLC acquired a new stake in Pfizer during the 3rd quarter valued at approximately $127,000. Oak Point Wealth Management acquired a new stake in Pfizer during the 4th quarter valued at approximately $165,000. Cerebellum GP LLC acquired a new stake in Pfizer during the 4th quarter valued at approximately $166,000. Finally, Lipe & Dalton lifted its stake in Pfizer by 6.9% during the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after acquiring an additional 300 shares during the period. Institutional investors own 71.19% of the company’s stock.
PFE has been the subject of several research reports. SunTrust Banks restated a “hold” rating and set a $40.00 price objective (up from $33.00) on shares of Pfizer in a research note on Monday, January 29th. Jefferies Group set a $39.00 price objective on shares of Pfizer and gave the company a “hold” rating in a research note on Monday, February 26th. Morningstar set a $38.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, January 30th. BMO Capital Markets set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, March 6th. Finally, Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $37.98 target price for the company. in a research note on Monday, January 15th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $39.20.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.56 by $0.06. The company had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The firm’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.47 EPS. equities research analysts expect that Pfizer will post 2.95 earnings per share for the current year.
In related news, insider Mikael Dolsten sold 13,986 shares of the business’s stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $35.85, for a total value of $501,398.10. Following the completion of the sale, the insider now owns 120,884 shares of the company’s stock, valued at approximately $4,333,691.40. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Charles H. Hill sold 42,393 shares of the business’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total transaction of $1,515,973.68. The disclosure for this sale can be found here. In the last three months, insiders sold 248,037 shares of company stock valued at $9,064,785. 0.06% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “Pfizer (PFE) Position Reduced by Truepoint Inc.” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://stocknewstimes.com/2018/04/20/pfizer-pfe-position-reduced-by-truepoint-inc.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.